High seroprevalence of SARS-CoV-2 in elderly care employees in Sweden

Johanna F. Lindahl, Tove Hoffman, Mouna Esmaeilzadeh, Björn Olsen, Reidar Winter, Stefan Amer, Christian Molnár, Ann Svalberg and Åke Lundkvist

*Department of Medical Biochemistry and Microbiology, Zoonosis Science Center, Uppsala University, Uppsala, Sweden; †Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden; ‡Department of Biosciences, International Livestock Research Institute, Hanoi, Vietnam; §Department of Medical Sciences, Zoonosis Science Center, Uppsala University, Uppsala, Sweden; ¶Department of Cardiology and Clinical Physiology, eHeart AB, Stockholm, Sweden; #Saltsjöbaden, Sweden

ABSTRACT
The COVID-19 pandemic is growing and spreading in the Swedish elderly care system during April 2020. The increasing number of employees on sick-leave due to COVID-19 created severe logistic problems. Some elderly care homes therefore started to screen their personnel to secure the safety of the elderly and to avoid unnecessary quarantine of potentially immune employees.

Secondary data from a screening with a COVID-19 rapid test for detection of SARS-CoV-2-specific IgM and IgG of 1,005 employees in 22 elderly care homes in Stockholm, Sweden, were analyzed. Seropositive employees were found in 21 out of the 22 care homes. In total, 23% (231/1,005) of the employees tested positive for antibodies against SARS-CoV-2, and 14.3% (144/1,005) were found positive for IgM (either alone or combined with IgG), indicating recent or present infection. Of those that tested seropositive, 46.5% did not report any clinical symptoms, indicating pre- or asymptomatic infections. Reported symptoms with the highest correlation with seropositivity were fever and loss of smell and taste.

These results suggest that antibody testing of employees in elderly care homes is valuable for surveillance of disease development and a crucial screening tool in the effort to decrease the death toll in this pandemic.

Background
The new viral pneumonia Coronavirus Disease 2019 (COVID-19), caused by the novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has since the first reported cases in January in Wuhan, Hubei province, China, rapidly developed into a global pandemic [1–3]. By mid-May 2020, COVID-19 has spread to all permanently inhabited continents, 213 countries, and had caused more than 4.9 million reported human cases globally, with more than 320,000 human deaths [4]. The total number of actual COVID-19 cases is likely much higher than the number of confirmed cases due to limited testing in many geographical areas.

The major clinical symptoms of COVID-19 resemble respiratory illnesses caused by other viruses, i.e. fever and dry cough [5–8]. Anosmia (loss of smell) and ageusia (loss of taste) have also been noted as early and sometimes the only symptoms [9–11]. In addition, the virus has been detected in completely asymptomatic individuals [12,13] and there are estimates that the true asymptomatic portion may be as high as 80% [14]. Increasing age is an important risk factor for fatal outcome in COVID-19, and co-morbidities such as hypertension, diabetes, and cardiovascular disease associated with poor outcomes are more common in the elderly [15–17]. The case fatality rate increases drastically after the age of 60, with >3% in patients above 60 and between 14% and 20% in those above 80 [18,19].

As in other parts of the world, COVID-19 has rapidly spread to Swedish elderly care homes and resulted in an increasing number of deaths. The Swedish government issued a formal recommendation against visiting elderly care homes on April 1 [20], in spite of the potential detrimental risks associated with a social isolation of the elderly [21]. Even so, 191 out of 313 (61.0%) elderly care homes in Stockholm had confirmed at least one case of COVID-19 among their residents by April 19 2020, and 380 out of the 921 (41.3%) COVID-19 total death toll in Stockholm occurred among the elderly care home residents [22]. In addition, the number of employees in the elderly care on sick-leave due to COVID-19 was rapidly increasing. The time point for a safe return to the workplace after COVID-19 is at present unknown, since the knowledge concerning the immunology as well as the potential increase in herd-immunity to COVID-19 is still most limited.
Large serological screenings of employees at elderly care homes are therefore urgently needed, and tools are increasingly becoming available. In a recent study, we evaluated a commercially available assay, the COVID-19 IgG/IgM rapid test cassette, developed for rapid detection of SARS-CoV-2-specific antibodies and found a specificity of 100% for immunoglobulin (Ig) M and 99.2% for IgG [23]. In the present study, we analyzed secondary data from elderly care homes in Stockholm, the capital of Sweden, where employees had been screened for antibodies by this rapid test.

**Material and methods**

This study analyzed secondary data made available from elderly care homes situated in Stockholm city and its suburbs in the North, West, and South distributed between approximately 59°7’24-59°25’32 N and 17°45’44-18°15’14 E (Figure 1), where employees had been tested using the COVID-19 IgG/IgM rapid test cassette (Zhejiang Orient Gene Biotech Co Ltd, Huzhou, Zhejiang, China), which has been described previously [23,24]. This test produces a line for SARS-CoV-2-specific IgM or IgG, or both. In addition to test results, the anonymous data set included age, gender, if the employee had been in contact with someone with COVID-19, and if the employee had any COVID-19 symptoms at the time of testing or during the preceding 2 months before the sampling. Some employees also specified clinical symptoms. The elderly care homes reported different data, and for most, only test results were reported. All tests were performed during the first 20 days of April 2020.

Data were managed in Excel and STATA 14.2 (Statcorp Ltd, College Station, Texas). The variable on having any symptoms did only include observations that had data of both present and past symptoms, no imputation of missing data was made. Analyses between categorical variables were performed with logistic regression (logit command), Chi2 test, or Fisher’s exact test when the assumptions for Chi2 test were not met. T-test was used to assess associations with age. Correlation between reported symptoms was tested with command pwcorr to ensure no correlation above 0.6. A multivariable model was built for seropositivity including symptoms associated with p < 0.2 in univariable analyses, as well as contact with COVID-19 cases, using m LOGIT, with elderly care home as a random effect. The model was optimized by removing variables with higher p-value than 0.05, if they did not affect other variables with more than 25%. All data were handled anonymously, and ethical approval was given by the Swedish Ethical Review Authority (2020–02047).

**Results**

The study included 1,005 employees from 22 different elderly care homes in Stockholm. Data on gender and age were available from nine of the homes, indicating that 17.0% (56/330) of the employees were males and that 40.1% (133/332) and 34.9% (116/332) belonged to the age groups 36–50 and 51–65, respectively. Data on potential contact with someone with COVID-19 were available for 331 employees from these nine homes and contacts were reported by 37.8% (125/331) and varied between the homes (p < 0.001) (Table 1). Nine employees (9/79, 11.4%) reported this contact to be private, while 70 (70/79, 88.6%) reported the contact to have been work related.

**Antibody reactivities and reported symptoms**

Of the 1,005 employees, 231 tested positive for either IgM or IgG (23.0%; 95% confidence interval (CI): 20.4–25.7%), while 105 (10.4%; 95% CI: 8.6–12.5%) were found positive for both IgM and IgG (Table 1). Thirty-nine employees (3.9%; 95% CI: 2.8–5.3%) tested positive for only IgM while 87 (8.7%; 95% CI: 7.0–10.6%) were positive for only IgG. Out of the 231 seropositive, 45.5% were positive for both IgM and IgG, 37.7% were positive for IgG only and 16.9% were positive for only IgM. Seropositive employees were detected in all except one of the elderly care homes.

![Figure 1. Map of the incidence of laboratory-confirmed COVID-19 cases [25] in Sweden as of April 23 2020, with the location of Stockholm marked with a star.](image-url)
Table 1. Serological responses of 1,005 employees to SARS-CoV-2 at 22 different elderly care homes in Stockholm, Sweden, and the number of employees that reported known contacts with COVID-19 cases.

| Home | Tested | Seropositive | IgM only | IgM and IgG | IgG only | Reported contact |
|------|--------|--------------|----------|-------------|----------|------------------|
|      |        | Number | %        | Number | %        | Number | %        | Number | %        | Number | %        | Number | %        | Number | %        | Number | %        |
| 1    | 50     | 12     | 24.0     | 1      | 2.0      | 7      | 14.0     | 4      | 8.0      | 24/50  | 48.0     |
| 2    | 65     | 9      | 13.8     | 0      | 0.0      | 6      | 9.2      | 3      | 4.6      | 22/62  | 35.5     |
| 3    | 37     | 8      | 21.6     | 0      | 0.0      | 5      | 13.5     | 3      | 8.1      | 14/37  | 37.8     |
| 4    | 112    | 32     | 28.6     | 8      | 7.1      | 13     | 11.6     | 11     | 9.8      | 20/27  | 74.1     |
| 5    | 33     | 8      | 24.2     | 2      | 6.1      | 6      | 18.2     | 0      | 0.0      | 6/32   | 18.8     |
| 6    | 25     | 10     | 40.0     | 2      | 8.0      | 5      | 20.0     | 3      | 12.0     | 0/25   | 0.0      |
| 7    | 17     | 5      | 29.4     | 0      | 0.0      | 4      | 23.5     | 1      | 5.9      | 10/17  | 58.8     |
| 8    | 73     | 15     | 20.5     | 0      | 0.0      | 10     | 13.7     | 5      | 6.8      |        |          |
| 9    | 35     | 5      | 14.3     | 3      | 8.6      | 0      | 0.0      | 2      | 5.7      |        |          |
| 10   | 7      | 0      | 0.0      | 0      | 0.0      | 0      | 0.0      | 0      | 0.0      |        |          |
| 11   | 44     | 17     | 38.6     | 3      | 6.8      | 14     | 31.8     | 0      | 0.0      |        |          |
| 12   | 11     | 2      | 18.2     | 0      | 0.0      | 2      | 18.2     | 0      | 0.0      |        |          |
| 13   | 60     | 9      | 15.0     | 0      | 0.0      | 2      | 3.3      | 7      | 11.7     |        |          |
| 14   | 51     | 11     | 21.6     | 1      | 2.0      | 5      | 9.8      | 5      | 9.8      |        |          |
| 15   | 42     | 19     | 45.2     | 4      | 9.5      | 8      | 19.0     | 7      | 16.7     |        |          |
| 16   | 80     | 15     | 18.8     | 1      | 1.3      | 7      | 8.8      | 7      | 8.8      |        |          |
| 17   | 73     | 21     | 28.8     | 5      | 6.8      | 3      | 4.1      | 13     | 17.8     |        |          |
| 18   | 22     | 4      | 18.2     | 1      | 4.5      | 1      | 4.5      | 2      | 9.1      |        |          |
| 19   | 68     | 9      | 13.2     | 1      | 1.5      | 1      | 1.5      | 7      | 10.3     |        |          |
| 20   | 19     | 2      | 10.5     | 1      | 5.3      | 0      | 0.0      | 1      | 5.3      |        |          |
| 21   | 46     | 17     | 37.0     | 5      | 10.9     | 6      | 13.0     | 6      | 13.0     | 29/46  | 63.0     |
| 22   | 35     | 1      | 2.9      | 1      | 2.9      | 0      | 0.0      | 0      | 0.0      | 0/35   | 0.0      |
| Total| 1005   | 231    | 23.0     | 39     | 3.9      | 105    | 10.4     | 87     | 8.7      | 125/331| 37.8     |

*Out of those answering this question

and the seroprevalence ranged from 0% to 45% (Figure 2, Table 1).

In total, 89.1% (409/459) of the employees, for which such data were available, reported no clinical symptom at the time of testing, while 10.9% (50/459) reported symptoms. Thirty-six percent of the employees that reported symptoms at sampling had IgM antibodies, while 24.9% of those not reporting symptoms were IgM positive (p = 0.09) (Table 2). Eighty-five percent (102/120) of the IgM positives did not have any clinical symptoms at the time of sampling, while 64.7% (33/51) had no symptoms during the preceding month, and 45.0% (27/60) were asymptomatic 1–2 months before testing. Including observations where both present and previous symptoms were known, a total of 35.8% (123/344) of the employees had reported symptoms at some point. There were more seropositive individuals among those that had reported symptoms (37.4%, 46/123) as compared to those with no symptoms (18.1%, 40/221) (p < 0.001). However, out of the seropositive employees, 46.5% (40/86) reported having no clinical symptoms during the last two months.

In some cases, employees also reported specific symptoms (Table 3). Loss of smell and taste (anosmia and ageusia) either at time of testing or the previous month were reported by 13 employees. Out of these, 69.2% were seropositive compared to 20.4% of those not reporting these symptoms (p < 0.001). Fever was

Figure 2. Serological results (as percentages and absolute numbers) among employees at 22 elderly care homes in Stockholm, Sweden.
reported by 23 employees and the seroprevalence was higher among employees reporting fever as compared to those not reporting fever (p = 0.003).

Risk factor analysis

Association with seropositivity was tested for gender, age, and contact with a COVID-19 case. Age and gender had no association with being seropositive, but those with previous contact with a COVID-19 case had an odds ratio (OR) 2.5 (95% CI: 1.5–4.2) higher than those without contact.

Multivariable model for seropositivity

Using a mixed effects model; loss of smell, fever, and contact with COVID-19 cases were strong predictors for seropositivity (Table 3). When combined with the other factors, headache was a confounder and had a slightly negative impact on the risks.

Discussion

In this study, we evaluated secondary data from elderly care homes in Stockholm, Sweden, where a commercial rapid test detecting SARS-CoV-2-specific IgM and IgG had been used to screen for antibody prevalence among employees. We found seropositive employees in 95.5% (21/22) of the investigated elderly care homes as well as a high seropositivity of IgM antibodies among the employees, often combined with IgG antibodies. The results indicated a recent spread of SARS-CoV-2 within elderly care in Stockholm and a potentially ongoing infection in a substantial portion of the employees. Antibody tests have lower sensitivities for recent infections [23], i.e. virus-specific antibody responses are usually not detected until a week after onset of disease, and therefore the actual seroprevalence may be slightly higher than what is estimated here. While there is a lack of publications on seroprevalence for SARS-CoV-2 in the Swedish population, there have been media reports of screenings conducted in two large hospitals, which found that 10% and 20% of employees had antibodies [26,27], indicating that elderly care employees may be an even more exposed group. A later media report of 7.3% seroprevalence in Stockholm confirms this suspicion [28].

Around half of the seropositive individuals (45% for IgM and 47% of all seropositives) in this study were pre- or asymptomatic, which is similar to the results in a study from Italy [12], but lower than the

### Table 2. Prevalence of IgM (either only IgM or combined with IgG) or only IgG among elderly care home employees with or without reported symptoms.

| Symptom                          | IgM positive (%) | IgG positive only (%) |
|----------------------------------|------------------|-----------------------|
| Symptoms at sampling             |                  |                       |
| Yes                              | 18/50 (36.0)     | 6/50 (12.0)           |
| No                               | 102/409 (24.9)   | 73/409 (17.8)         |
| Symptom within the last month    |                  |                       |
| Yes                              | 18/77 (23.4)*    | 8/77 (10.4)           |
| No                               | 33/254 (13.0)    | 15/254 (5.9)          |
| Symptoms 1–2 months earlier     |                  |                       |
| Yes                              | 2/21 (9.5)       | 1/21 (4.8)            |
| No                               | 49/310 (15.8)    | 22/310 (7.1)          |

*Significant at p < 0.05 compared to the row below.

| Predictor              | Univariable | Multivariable |
|------------------------|-------------|---------------|
|                        | Seropositive (%) | p-Value | Odds ratio (95% CI) | p-Value |
| Contact with case      |             |           |                     |         |
| Yes                    | 125         | 40 (32.0) | 2.4 (1.3–4.4)       | 0.005   |
| No                     | 206         | 33 (16.0) |
| Reported symptoms      |             |           |                     |         |
| Aches                  |             |           |                     |         |
| Yes                    | 11          | 4 (36.4)  | 0.25                | Not included |
| No                     | 324         | 70 (21.6) |
| Anosmia/ageusia        |             |           |                     |         |
| Yes                    | 13          | 9 (69.2)  | <0.001              | 6.4 (1.6–25.8) | 0.009 |
| No                     | 323         | 66 (20.4) |
| Cold, sore throat      |             |           |                     |         |
| Yes                    | 41          | 14 (34.2) | 0.06                | Not included |
| No                     | 297         | 63 (21.2) |
| Cough                  |             |           |                     |         |
| Yes                    | 37          | 12 (32.4) | 0.11                | Not included |
| No                     | 298         | 62 (20.8) |
| Dyspnea                |             |           |                     |         |
| Yes                    | 14          | 6 (42.9)  | 0.06                | Not included |
| No                     | 321         | 68 (21.2) |
| Fever                  |             |           |                     |         |
| Yes                    | 23          | 11 (47.8) | 0.003               | 2.8 (1.0–8.1) | 0.049 |
| No                     | 314         | 65 (20.7) |
| Headache               |             |           |                     |         |
| Yes                    | 29          | 11 (37.9) | 0.04                | 0.4 (0.1–1.4) | 0.16 |
| No                     | 309         | 66 (21.4) |
| Tired                  |             |           |                     |         |
| Yes                    | 43          | 13 (30.2) | 0.18                | Not included |
| No                     | 293         | 62 (21.2) |

p-Values < 0.05 of significance are indicated in bold.
estimate of 80% [14]. Previous studies in nursing homes have found that there may be PCR-positive pre- or asymptomatic residents during an outbreak, and the same study found 19% of tested staff being positive [29]. While it is believed that most transmissions occur from symptomatic carriers through coughing or sneezing, it has also been suggested that virus could be spread through droplets or aerosols while talking [30,31], thus motivating the use of proper face masks by elderly care home employees during the pandemic. In this study, symptoms were self-reported, and data on exact symptoms were lacking for most individuals. It may be that some respondents did not want to report symptoms since they would not have been allowed to work, and therefore there may be a social desirability response bias [32], where symptoms were underreported, potentially particularly from those that tested positive. Based on the available data it seems that fever and loss of taste and smell, together with the knowledge about possible contact with a COVID-19 case, may be the best predictors for seropositivity among elderly care home employees, and it would be recommended to use molecular methods to test employees having those symptoms.

There was a correlation in the presented data between employees being seropositive and reporting contact with COVID-19 cases. Given the fragility and thus the susceptibility of the elderly to COVID-19 and the importance of securing staffing in the elderly care homes, there is a strong incitement for testing all employees in this sector. Since the rapid antibody test only detects antibodies in a qualitative manner, it would be desirable to perform sequential testing in order to monitor serological changes over time. IgM is usually a biomarker for acute infections. It might therefore seem straightforward to isolate individuals who test positive for IgM. However, our previous study using the same rapid test showed no case with IgM positivity only [23] and previous studies on SARS-CoV indicate that IgM and IgG, a biomarker for immunity, may develop almost simultaneously [33,34]. An experiment in rhesus macaques could detect IgG within 3 days post infection [35]. It would therefore be desirable to combine serological testing with a PCR test that diagnoses the virus in order to better understand the correlation between seropositivity and viral presence. However, since PCR only detects viral RNA, it would be valuable to conduct viral isolations to understand when infected individuals truly start being non-infectious. Although it is believed that IgM antibodies may develop already within some days post-infection in some individuals, the median seroconversion for IgM and IgG to SARS-CoV-2 was 12 and 14 days, respectively, in a recent study [36]. Thus, the sensitivity of any antibody tests is likely low during the first phase of the infection, which would motivate repeated testing. A SARS-CoV-2 infection is likely followed by immunity [35], and developed antibodies have been demonstrated to be neutralizing (inhibiting viral replication) using plaque reduction neutralization test (PRNT) and microneutralization tests [37–39] but the duration and extent of immunity is at present unknown and should be investigated during the progression of the pandemic, as well as the role of different antibody classes, including IgA.

Given the urgency of the situation in the health and elderly care, the present study proved antibody testing to be a fast and efficient way to map and isolate infected employees in order to prevent transmission, as well as to secure staffing by revealing those with IgG antibodies and potential immunity. However, more research on the development of antibodies during COVID-19, combined with molecular studies, is needed in order to make proper recommendations on when exposed staff can safely return to work. With the elderly of 80 years of age and older having a case fatality rate of potentially as high as 20% [19], this risk group needs to be protected as much as possible.

In conclusion, our results indicate a high prevalence of antibodies against SARS-CoV-2 and a high percentage of pre- or asymptomatic infections among employees in elderly care homes, and thus a risk for the elderly to become infected by their care givers. Employees must therefore be provided with proper personal protective equipment, and training in how to use it in order to prevent further spread of the virus in the elderly care settings.

Disclosure statement

No potential conflict of interest was reported by the authors.

Notes on contributors

Johanna Lindahl, PhD, DVM, is a veterinary epidemiologist working at Uppsala University, jointly appointed with Swedish University of Agricultural Sciences as well as International Livestock Research Institute (ILRI) in Nairobi Kenya. Her research focus on food safety, and vector-borne, zoonotic and emerging infectious diseases in developing countries, mainly East Africa and South and Southeast Asia.

Christian Molnár, Specialist in Family medicine, Head of Department, Familjeläkarna Geriatrics, Member of the board of experts for the Health of Elderly, Drug Therapeutic Committee of the Region of Stockholm.

Ann Svalberg is the Head of Coordination, at Familjeläkarna.

Björn Olsen is professor and senior consultant of infectious diseases at Uppsala University and University hospital. His main research focus is zoonotic infections, emerging
infections and pandemics. He is one of the founders of Zoonosis Science Center at Uppsala University.

**Tove Hoffman** is a PhD student at the Department of Medical Sciences, Uppsala University, Sweden. Her doctoral studies mainly concern the involvement of northward migratory birds in the dispersal of ticks and tick-borne pathogens.

**Åke Lundkvist** PhD, is Professor in virology and one of the founders of the Zoonosis Science Center at Uppsala University. His work focuses on basic virological, pathogenetic, ecological and epidemiological studies on zoonotic viruses and their vectors and hosts.

**Reidar Winter** is the CEO of eHeart AB, Senior Consultant Cardiologist MD PhD, Former Professor of Medical Technology, KTH.

**Stefan Amér** is a Specialist in Ophthalmology and one of the founders of Familjeläkarna. He is Chairman of Säbo-rädet (the Council for Medical Organizations at Nursing Homes in the County of Stockholm)

**Mouna Esmaelzadeh** is a medical doctor and neuroscientist from the Karolinska Institutet, Sweden. She was one of the founders of SciLife Clinic (2009-2016), a pioneering medical clinic within preventive and personalized medicine, using technologies such as magnetic resonance imaging and genetic sequencing to map and prevent diseases. In addition to her MD, PhD., she has a master’s degree in philosophy from the University of Oslo and Stockholm University.

**ORCID**

Johanna F. Lindahl [http://orcid.org/0000-0002-1175-0398](http://orcid.org/0000-0002-1175-0398)

Tove Hoffman [http://orcid.org/0000-0003-2239-9078](http://orcid.org/0000-0003-2239-9078)

Åke Lundkvist [http://orcid.org/0000-0001-8608-6551](http://orcid.org/0000-0001-8608-6551)

**References**

[1] Guarner J. Three emerging coronaviruses in two decades: the story of SARS, MERS, and now COVID-19. Am J Clin Pathol. 2020 Mar 9;153(4):420–421.

[2] De Wit E, Van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses [Internet]. Nature Reviews Microbiology Nature Publishing Group; Aug 1;2016:523–534. Available from: www.nature.com/nrmicro

[3] Hilgenfeld R, Peiris M. From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Vol. 100. Antiviral Research. Elsevier; 2013. p. 286–295.

[4] Worldometer. Coronavirus cases [Internet]. Worldometer. 2020 [cited 2020 May 19]. Available from: https://www.worldometers.info/coronavirus/coronavirus-cases/daily-cases

[5] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. J Am Med Assoc. 2020;323(11):1061.

[6] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497–506.

[7] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. J Am Med Assoc. 2020;323(13):1239.

[8] Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020 Jan 29;382(13):1199–1207.

[9] Vaira LA, Salzano G, Deiana G, et al. Anosmia and ageusia: common findings in COVID-19 patients. Laryngoscope. [Internet]. 2020 Apr 1;130(7):1787.

[10] Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Oto-Rhino-Laryngol. [Internet]. 2020 Apr 6 [cited 2020 Apr 12];14:ed98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32269598.

[11] Russell B, Moss C, Riggi A, et al. Anosmia and ageusia are emerging as symptoms in patients with COVID-19: what does the current evidence say? ErcanCmeDicscience. [Internet]. 2020 [cited 2020 Apr 12];14:ed98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32269598.

[12] ECDC. Novel coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK – sixth update [Internet]. Stockholm, Sweden; 2020. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/RRA-sixth-update-Outbreak-of-novel-coronavirus-disease-2019-COVID-19.pdf

[13] Mizumoto K, Kagaya K, Zarebski A, et al. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance. [Internet]. 2020 Mar 12 [cited 2020 Mar 20];25(10):2000180. Available from: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.10.2000180

[14] Day M. Covid-19: four fifth s of cases are asymptomatic, China figures indicate. BMJ. [Internet]. 2020 Apr 2 [cited 2020 Apr 12];369:m1375. Available from: http://www.bmj.com/lookup/doi/10.1136/bmj.m1375

[15] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–1062.

[16] Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med. 2020 Mar 19;26(4):506–510.

[17] Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020 Mar 12;94:91–95.

[18] Duddell C, Riffe T, Acosta E, et al. Monitoring trends and differences in COVID-19 case fatality rates using decomposition methods: contributions of age structure and age-specific fatality. medRxiv. 2020 Apr 8. 2020.03.31.20048397.

[19] Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA - J Am Med Assoc. 2020. DOI:10.1001/jama.2020.4683.

[20] Ministry of Health and Social Affairs Sweden. Decisions and guidelines in the Ministry of Health
and Social Affairs’ policy areas to limit the spread of the COVID-19 virus [Internet]. 2020 [cited 2020 Apr 19]. Available from: https://www.gov.se/articles/2020/04/s-decisions-and-guidelines-in-the-ministry-of-health-and-social-affairs-policy-areas-to-limit-the-spread-of-the-covid-19-virusy-sida/

[21] Armitage R, Nellums LB. COVID-19 and the consequences of isolating the elderly. Lancet Public Heal. 2020 Mar;5(5):e256.

[22] Stockholm R. 19 april: lägesrapport om arbetet med det nya coronaviruset [Internet]. 2020 [cited 2020 Apr 22]. Available from: https://www.slb.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/04/19-april-lagesrapport-om-arbetet-med-det-nya-coronaviruset/

[23] Hoffman T, Nisen K, Krambrich J, et al. Evaluation of a COVID-19 IgM and IgG rapid test: an efficient tool for assessment of past exposure to SARS-CoV-2. Infect Ecol Epidemiol. [Internet]. 2020 Jan 1 [cited 2020 Apr 14];10(1):1754538. Available from: https://www.tandfonline.com/doi/full/10.1080/20008686.2020.1754538

[24] Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. [Internet]. 2020 Feb 27 [cited 2020 Apr 4];jmv.25727. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25727.

[25] Public Health Agency of Sweden. Confirmed cases of COVID-19 in Sweden [Internet]. 2020 [cited 2020 Apr 23]. Available from: https://www.folkhalsomyndigheten.se/smittskydd-beredskap/utbrott/aktuella-utbrott/covid-19/bekraftade-fall-i-sverige/

[26] Karolinska: 15 procent av stockholmarna kan ha haft corona. DNSE [Internet]. 2020 [cited 2020 May 19]. Available from: https://www.dn.se/sthlm/studie-15-procent-av-arbetande-stockholmare-smittade-av-coronaviruset/

[27] Var femte anställd på Danderyd har antikroppar mot covid-19. DNSE [Internet]. 2020 [cited 2020 May 19]; Available from: https://www.dn.se/sthlm/var-femte-anstalld-pa-danderyds-sjukhus-har-haft-smittan/

[28] Corona i Sverige – antikroppstester klara | svD [Internet]. [cited 2020 May 20]; Available from: https://www.svd.se/folkhalsomyndigheten-haller-presstraff-om-viruslaget

[29] Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. [Internet]. 2020 Apr 24 [cited 2020 Apr 25];NEJMoa2008457. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2008457

[30] Anfinrud P, Stadnytskyi V, Bax CE, et al. Visualizing speech-generated oral fluid droplets with laser light scattering. N Engl J Med. [Internet]. 2020 Apr 15 [cited 2020 Apr 21];NEJMc2007800. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32294341

[31] Meselson M. Droplets and aerosols in the transmission of SARS-CoV-2. N Engl J Med. [Internet]. 2020 Apr 15 [cited 2020 Apr 21];NEJMc2009324. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32294374

[32] Tripepi G, Jager KJ, Dekker FW, et al. Selection bias and information bias in clinical research. Vol. 115. Nephron - Clinical Practice. Nephron Clin Pract; 2010.

[33] Li G, Chen X, Xu A. Profile of specific antibodies to the SARS-associated coronavirus. Vol. 349. N Engl J Med. 2003;349(5):508–509.

[34] Hsuah PR, Huang LM, Chen PJ, et al. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect. 2004 Dec 1;10(12):1062–1066.

[35] Bao L, Deng W, Gao H, et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv. 2020 Mar 14. 2020.03.13.990226.

[36] Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. [Internet]. 2020 Mar 28. Available from:. DOI:10.1093/cid/ciaa344

[37] Nma OKBA, Muller MA, Li W, et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv. [Internet]. 2020 [cited 2020 Apr 1];2020.03.18.20038059. Available from: https://www.medrxiv.org/content/10.1101/2020.03.18.20038059v1

[38] Haveri A, Šmura T, Kuivinen S, et al. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland. Eurosurveillance. [Internet]. 2020 Mar 19;25(11):1.

[39] Perera RA, Mok CK, Tsang OT, et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Eurosurveillance. [Internet]. 2020 Apr 23;25(16):2000421.